AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study
28/09/2021 – AB Science today announced that a new clinical trial with masitinib in patients with symptomatic mild and moderate COVID-19 has been approved by the Regulatory Authorities of Russia and South Africa